Search Results - "Killelea, Amy"

Access to a novel first-line single-tablet HIV antiretroviral regimen in Affordable Care Act Marketplace plans, 2018-2020 by Khazanchi, Rohan, Powers, Samuel, Killelea, Amy, Strumpf, Andrew, Horn, Tim, Hamp, Auntré, McManus, Kathleen A

“…A pillar of the United States' Ending the HIV Epidemic (EHE) initiative is to rapidly provide antiretroviral therapy (ART) in order to achieve HIV viral…”
Get full text

Economic benefits of the United States’ AIDS drug assistance Program: A systematic review of cost analyses to guide research and policy priorities by McManus, Kathleen A., Strumpf, Andrew, Killelea, Amy, Horn, Tim, Hamp, Auntré, Keim-Malpass, Jessica

“…•The AIDS Drug Assistance Program (ADAP) is a $2.4 billion a year program.•Little formal economic analysis of the ADAP in the literature.•The few economic…”
Get full text

Ryan White HIV/AIDS Part B and AIDS Drug Assistance Programs during COVID-19: safety net public health programs’ challenges and innovations by McManus, Kathleen A., Strumpf, Andrew M., Killelea, Amy, Horn, Tim, Steen, Amber, An, Zixiao, Schurman, Elizabeth, Hamp, Auntré, Keim-Malpass, Jessica

“…Introduction We characterized the challenges and innovations of states’ Ryan White HIV/AIDS Program (RWHAP) Part B programs, including AIDS Drug Assistance…”
Get full text

Investing in National HIV PrEP Preparedness by Johnson, Jeremiah, Killelea, Amy, Farrow, Kenyon

“…The limited new funding allocated to the “Ending the HIV Epidemic in the U.S.” initiative could be a first step toward building a national PrEP program for…”
Get full text

Long-Acting Cabotegravir for HIV Prevention: Issues of Access, Cost, and Equity by Sharfstein, Joshua M, Killelea, Amy, Dangerfield, Derek

“…Sharfstein et al examine the issues of access, cost, and equity of long-acting cabotegravir for HIV prevention. On December 20, 2021, the US Food and Drug…”
Get full text

Perverse Incentives — HIV Prevention and the 340B Drug Pricing Program by Marcus, Julia L., Killelea, Amy, Krakower, Douglas S.

“…A decade after preexposure prophylaxis against HIV became available, less than a quarter of people in the United States who could benefit from PrEP are taking…”
Get full text

HIV Prevention and the 340B Drug Pricing Program by Hall, Christopher S., Marcus, Julia L., Killelea, Amy, Krakower, Douglas S.

“…To the Editor: In their Perspective article, Marcus et al. (June 2 issue) 1 warn that provision of human immunodeficiency virus (HIV) preexposure prophylaxis…”
Get full text

HIV Prevention and the 340B Drug Pricing Program. Reply by Marcus, Julia L, Killelea, Amy, Krakower, Douglas S

Get full text

Amy Killelea, Natalie O. Cramer, and Michael Weir Comment by Killelea, Amy, Cramer, Natalie O, Weir, Michael

“…Earlier in 2019, the Trump administration announced a goal to end the HIV epidemic in the United States by 2030 ("Ending the HIV Epidemic: A Plan for America"…”
Get full text

Associated Costs Are a Barrier to HIV Preexposure Prophylaxis Access in the United States by Srikanth, Karishma, Killelea, Amy, Strumpf, Andrew, Corbin-Gutierrez, Edwin, Horn, Tim, McManus, Kathleen A

“…HIV pre-exposure prophylaxis (PrEP), a biomedical HIV prevention intervention, reduces the risk of HIV acquisition by upwards of 90% for sexual encounters and…”
Get full text

Associated Costs are a Barrier to HIV Pre-exposure Prophylaxis Access in the United States by Srikanth, Karishma, Killelea, Amy, Strumpf, Andrew, Corbin-Gutierrez, Edwin, Horn, Tim, McManus, Kathleen A.

“…There are disparities in PrEP uptake among groups at higher risk for HIV. The current gap in financial assistance for PrEP-associated medical visits and…”
Get full text

Clustering affordable care act qualified health plans to understand how and where insurance facilitates or impedes access to HIV prevention by Powers, Samuel D., Schmidt, Karen M., Killelea, Amy, Strumpf, Andrew, McManus, Kathleen A.

Get full text

Insurance coverage and financing landscape for HIV treatment and prevention in the USA by Kates, Jennifer, Dawson, Lindsey, Horn, Tim H, Killelea, Amy, McCann, Nicole C, Crowley, Jeffrey S, Walensky, Rochelle P

“…In 2010, the US health insurance system underwent one of its most substantial transformations with the passage of the Affordable Care Act, which increased…”
Get full text

Considerations for Modernized Criminal HIV Laws and Assessment of Legal Protections Against Release of Identified HIV Surveillance Data for Law Enforcement by Galletly, Carol L, Benbow, Nanette, Killelea, Amy, Lazzarini, Zita, Edwards, Ruth

“…In November 2018, the Centers for Disease Control and Prevention distributed guidance to funded agencies under its Integrated HIV Surveillance and Prevention…”
Get full text

Addressing Ethical Challenges in US-Based HIV Phylogenetic Research by Dawson, Liza, Benbow, Nanette, Fletcher, Faith E, Kassaye, Seble, Killelea, Amy, Latham, Stephen R, Lee, Lisa M, Leitner, Thomas, Little, Susan J, Mehta, Sanjay R, Martinez, Omar, Minalga, Brian, Poon, Art, Rennie, Stuart, Sugarman, Jeremy, Sweeney, Patricia, Torian, Lucia V, Wertheim, Joel O

“…Abstract In recent years, phylogenetic analysis of HIV sequence data has been used in research studies to investigate transmission patterns between individuals…”
Get full text

870. Coverage, Cost Sharing, and Out-of-Pocket Costs for Single-Tablet HIV Antiretroviral Regimens in Qualified Health Plans in the United States, 2018-2020 by Khazanchi, Rohan, Powers, Samuel D, Killelea, Amy, McManus, Kathleen A

“…Abstract Background A key pillar of the US “Ending the HIV Epidemic” (EHE) plan is rapidly providing antiretroviral therapy (ART) to achieve viral suppression…”
Get full text

Financing and Delivering Pre-Exposure Prophylaxis (PrEP) to End the HIV Epidemic by Killelea, Amy, Johnson, Jeremiah, Dangerfield, Derek T, Beyrer, Chris, McGough, Matthew, McIntyre, John, Gee, Rebekah E, Ballreich, Jeromie, Conti, Rena, Horn, Tim, Pickett, Jim, Sharfstein, Joshua M

“…The U.S. has the tools to end the HIV epidemic, but progress has stagnated. A major gap in U.S. efforts to address HIV is the under-utilization of medications…”
Get more information

Access to Medications for Opioid Use Disorder for Persons With Human Immunodeficiency Virus in the United States: Gaps in Coverage by State AIDS Drug Assistance Programs by McManus, Kathleen A, Davy-Mendez, Thibaut, Killelea, Amy, Schranz, Asher J

“…Abstract Life-saving medications for opioid use disorder are inaccessible for people with human immunodeficiency virus relying on the AIDS Drug Assistance…”
Get full text

Geographic Variation in Qualified Health Plan Coverage and Prior Authorization Requirements for HIV Preexposure Prophylaxis by McManus, Kathleen A, Fuller, Benjamin, Killelea, Amy, Strumpf, Andrew, Powers, Samuel D, Rogawski McQuade, Elizabeth T

“…HIV preexposure prophylaxis (PrEP) is a key component of the Ending the HIV Epidemic (EHE) Initiative to curb new HIV diagnoses. In October 2019,…”
Get full text

Regional Disparities in Qualified Health Plans’ Prior Authorization Requirements for HIV Pre-exposure Prophylaxis in the United States by McManus, Kathleen A., Powers, Samuel, Killelea, Amy, Tello-Trillo, Sebastian, Rogawski McQuade, Elizabeth

“…Importance With the goal of ending the HIV epidemic in the United States, access to HIV pre-exposure prophylaxis (PrEP) is essential to help curb new HIV…”
Get full text